Follicular Lymphoma | Clinical

Tisagenlecleucel Leads to High CR Rate in Heavily Pretreated, R/R Follicular Lymphoma

February 22, 2021

Tisagenlecleucel induced a significant number of complete responses in patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the phase 2 ELARA trial as of the interim analysis of the study.

Precision Medicine Shapes the Future of Follicular Lymphoma Management

February 19, 2021

In an interview with Targeted Oncology, Carla Casulo, MD, discussed the modern management of patients with relapsed/refractory follicular lymphoma. She also explained how ongoing research may shape the future of the field.

Tisagenlecleucel Safe and Effective in Relapsed/Refractory Follicular Lymphoma

January 13, 2021

Anti-CD19 chimeric antigen receptor T-cell therapy with tisagenlecleucel has shown efficacy for the treatment of patients with extensively treated and refractory follicular lymphoma, according to preliminary phase 2 data from the ELARA clinical trial.

Rituximab Plus Anthracycline-Based Chemotherapy Prolongs Survival Long-Term in Follicular Lymphoma

January 08, 2021

Rituximab added to standard anthracycline-based chemotherapy demonstrated significant improvements in progression-free survival as well as overall survival as treatment of patients with follicular lymphoma, according to 35-year follow-up results of patients treated through the Nebraska Lymphoma Study Group.